Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization

BACKGROUND: The efficacy‐effectiveness gap between randomized trial and real‐world evidence regarding the clinical benefit of ipilimumab for metastatic melanoma (MM) has been well characterized by previous literature, consistent with initial concerns raised by health technology assessment agencies (...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Brandon, Dai, Wei Fang, Croxford, Ruth, Isaranuwatchai, Wanrudee, Beca, Jaclyn, Menjak, Ines B., Petrella, Teresa M., Mittmann, Nicole, Earle, Craig C., Gavura, Scott, Mercer, Rebecca E., Hanna, Timothy P., Chan, Kelvin K. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242360/
https://www.ncbi.nlm.nih.gov/pubmed/36999965
http://dx.doi.org/10.1002/cam4.5862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242360/
https://www.ncbi.nlm.nih.gov/pubmed/36999965
http://dx.doi.org/10.1002/cam4.5862

Ejemplares similares